Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Juan Iovanna

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1822-2237; OpenAlex author ID A5066948009. Sources: OpenAlex.

Their work

Papers
125 (first author 9, last author 34)
Trials
0
Grants
0
Labs led
1
Collaborators
220
Papers, trials and grants by year

2011: 4 papers · 2012: 7 papers · 2013: 4 papers · 2014: 4 papers · 2015: 8 papers · 2016: 6 papers · 2017: 10 papers · 2018: 9 papers · 2019: 9 papers · 2020: 8 papers · 2021: 15 papers · 2022: 9 papers · 2023: 7 papers · 2024: 4 papers · 2025: 11 papers · 2026: 10 papers

Papers 50 of 125

  1. Decoding the Integrated Stress Response of Pancreatic Cancer: Identifying a Serine-dependent Tumor Subset Under Metabolic Relationships With CAFs. Co-author DOI 10.1002/advs.202515740↗
  2. When defense turns dangerous: The dual nature of senescence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2026.105328↗
  3. Evaluating the therapeutic role of salvianolic acid A on pancreatic cancer cells through interaction with the intrinsically disordered protein NUPR1. Co-author DOI 10.1016/j.ijbiomac.2025.149435↗
  4. Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. Last author DOI 10.1016/j.isci.2026.115164↗
  5. Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2026.102920↗
  6. Single-cell transcriptomic profiling of patient-derived pancreatic ductal adenocarcinoma primary cell cultures. Co-author DOI 10.1038/s41597-026-07380-3↗
  7. A comprehensive proteomic dataset of secretomes from primary pancreatic cancer cell cultures. Co-author DOI 10.1038/s41597-026-07902-z↗
  8. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  9. Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. Co-author DOI 10.3390/epigenomes10010019↗
  10. GATA4 loss promotes mutant Kras -driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions Co-author DOI 10.64898/2026.05.22.724502↗
  11. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Co-author DOI 10.1002/path.6398↗
  12. Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. Co-author DOI 10.1002/ueg2.70124↗
  13. Reply to the Letter to the Editor 'AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma' by Y. Shimazu. Co-author DOI 10.1016/j.annonc.2024.09.016↗
  14. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  15. KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2025.102421↗
  16. Understanding the heterogeneity of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102479↗
  17. Correction to "Novel Triazole Ribonucleoside Down-Regulates Heat Shock Protein 27 and Induces Potent Anticancer Activity on Drug-Resistant Pancreatic Cancer". Co-author DOI 10.1021/acs.jmedchem.5c02592↗
  18. Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer. Co-author DOI 10.1038/s41389-025-00591-0↗
  19. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Co-author DOI 10.1073/pnas.2424051122↗
  20. The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Last author DOI 10.1093/oncolo/oyaf083↗
  21. E-Cadherin Is a Structuring Component of Invadopodia in Pancreatic Cancer. Co-author DOI 10.1111/jcmm.70608↗
  22. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  23. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  24. Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer. Last author DOI 10.3389/fonc.2024.1437200↗
  25. The xenobiotic transporter ABCC4/MRP4 promotes epithelial mesenchymal transition in pancreatic cancer. Co-author DOI 10.3389/fphar.2024.1432851↗
  26. Stroma-targeting strategies in pancreatic cancer: a double-edged sword. First author DOI 10.1007/s13105-022-00941-1↗
  27. Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. Last author DOI 10.1016/j.ebiom.2023.104602↗
  28. Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. Co-author DOI 10.1016/j.ebiom.2023.104634↗
  29. Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. Co-author DOI 10.1016/j.isci.2023.106899↗
  30. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-023-39026-y↗
  31. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.11.035↗
  32. [The mRNA vaccine for the treatment of pancreatic cancer is here to stay]. Co-author PMID 37582144↗
  33. Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. Last author DOI 10.1002/cac2.12335↗
  34. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Last author DOI 10.1002/cac2.12365↗
  35. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  36. Iron-Sensitive Prodrugs That Trigger Active Ferroptosis in Drug-Tolerant Pancreatic Cancer Cells. Co-author DOI 10.1021/jacs.2c03973↗
  37. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. Last author DOI 10.1038/s41698-022-00299-z↗
  38. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Co-author DOI 10.1101/2022.01.04.474951↗
  39. CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. Co-author DOI 10.1126/scisignal.abg8191↗
  40. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. Co-author DOI 10.15252/embj.2021110466↗
  41. [An "a la carte" treatment for patients with pancreatic adenocarcinoma]. Co-author PMID 35904914↗
  42. Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. Co-author DOI 10.1002/exp.20210003↗
  43. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.annonc.2020.10.601↗
  44. Targeting REG3β limits pancreatic ductal adenocarcinoma progression through CTGF downregulation. Last author DOI 10.1016/j.canlet.2021.08.024↗
  45. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. Last author DOI 10.1016/j.ebiom.2021.103332↗
  46. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. Co-author DOI 10.1016/j.ebiom.2021.103541↗
  47. Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. Co-author DOI 10.1016/j.ejca.2021.06.038↗
  48. Combating pancreatic cancer chemoresistance by triggering multiple cell death pathways. First author DOI 10.1016/j.pan.2021.01.010↗
  49. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer Co-author DOI 10.1016/j.pan.2021.05.117↗
  50. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Co-author DOI 10.1016/j.tranon.2020.100965↗

Closest collaborators

The 25 strongest of 220 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nelson Dusetti · 71 shared papers, 2011–2026 · strength 10.48
  2. Nicolas Alejandro Fraunhoffer · 28 shared papers, 2019–2026 · strength 5.53
  3. Rémy Nicolle · 23 shared papers, 2017–2026 · strength 3.00
  4. Odile Gayet · 28 shared papers, 2015–2026 · strength 2.79
  5. Julie Roques · 22 shared papers, 2015–2026 · strength 2.51
  6. Patricia Santofimia‐Castaño · 12 shared papers, 2018–2026 · strength 2.26
  7. Raul A. Urrutia · 20 shared papers, 2012–2026 · strength 2.21
  8. Brice Chanez · 10 shared papers, 2022–2026 · strength 2.09
  9. Philippe Soubeyran · 13 shared papers, 2018–2026 · strength 1.97
  10. Jerome F. Cros · 14 shared papers, 2017–2026 · strength 1.91
  11. Pascal R. Hammel · 11 shared papers, 2012–2026 · strength 1.81
  12. Gwen Alyce Lomberk · 18 shared papers, 2012–2026 · strength 1.79
  13. Analía Meilerman Abuelafia · 11 shared papers, 2019–2026 · strength 1.76
  14. Daniel Grasso · 8 shared papers, 2012–2026 · strength 1.44
  15. Jean‐Baptiste Bachet · 12 shared papers, 2012–2026 · strength 1.41
  16. Eduardo Chuluyán · 9 shared papers, 2015–2026 · strength 1.39
  17. Cindy Neuzillet · 7 shared papers, 2021–2026 · strength 1.29
  18. Vinciane Rebours · 6 shared papers, 2022–2025 · strength 0.89
  19. Abdessamad El Kaoutari · 7 shared papers, 2020–2023 · strength 0.87
  20. Richard Tomasini · 13 shared papers, 2013–2022 · strength 0.85
  21. Fabienne Guillaumond · 11 shared papers, 2013–2023 · strength 0.83
  22. Marc F. Giovannini · 12 shared papers, 2011–2023 · strength 0.77
  23. Anthony Turpin · 4 shared papers, 2024–2026 · strength 0.76
  24. Sophie Vasseur · 12 shared papers, 2013–2022 · strength 0.76
  25. Céline Loncle · 17 shared papers, 2011–2021 · strength 0.76

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.